Latest article
Bayer’s Finerenone Meets Major Endpoint in Section III FIGARO-DKD Cardiovascular Outcomes Research in Sufferers...
WHIPPANY, NJ - (BUSINESS WIRE) - Bayer's phase III cardiovascular outcome study FIGARO-DKD evaluating the efficacy...
asensei introduces asensei.ai, A Developer Platform To Add Linked Teaching™ To Any Sport Or...
"We want our customers to focus on providing the most comprehensive and beneficial coaching experience possible and not trying to train a machine to...